International Journal of Surgery and Surgical Sciences (IJSSS)
Open Access
Subscription Access
STUDY OF METABOLIC, SOCIO-ECONOMIC AND ANTHROPOMETRIC FACTOR IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA (BPH)
Abstract
Despite the high impact of Benign prostatic hyperplasia (BPH) on public health, the pathogenesis of BPH is still unresolved. Indeed, although multiple theories have been proposed, the etiology of BPH still remains uncertain in some aspects. Several mechanisms seem to be involved in the development and progression of BPH. BPH is the most common benign tumor in men, and its incidence is age related. Evidence for socio-demographic differences in the odds of BPH or lower urinary tract symptoms (LUTS) is conflicting.
This is observational study of 100 patients of BPH admitted to surgery wards. Patients were interviewed for history and clinical examination was conducted. Anthropological parameters were recorded and investigations related to study were done. In present study we have compared the relationship of Benign Prostatic Hyperplasia with age, PSA, testosterone level, BMI, WHR, components of metabolic syndrome like blood sugar level and lipid profile and socio-economic status.
Keywords
References
Ando S, Rubens R, and Rottiers R. (1984). “Androgen plasma levels in male diabetics”, J Endocrinol Invest, Vol.7, pp.21-24.
Ansari MAJ, Dilruba B, and Fakhrul I. (2008). “Serum sex steroids, gonadtrophins and sex hormone-binding globulin in prostatic hyperplasia”, Ann Saudi Med, Vol.28(3), pp.174-178.
Araki H, Watanabe H, and Mishina T, et al. (1983). “High-risk group for benign prostatic hypertrophy”, Prostate, Vol.4, pp.253-264.
Arrighi HM, Metter EJ, Guess HA, and Fozzard JL. (1991). “Natural history of benign prostatic hyperplasia and risk of prostatectomy, the Baltimore Longitudinal Study of Aging”, Urology Vol.35(Suppl), pp.4-8.
Badia X, Rodriguez F, and Carballido J, et al. (2001). “Influence of sociodemographic and health status variables on the American Urological Association symptom scores in patients with lower urinary tract symptoms”, Urology, Vol.57, pp.71-77.
Berry SJ, Coffey DS, and Walsh PC, et al. (1984). “The development of human benign prostatic hyperplasia with age”, J Urol, Vol.132(3), pp.474-479.
Burke JP, Rhodes T, Jacobson DJ, McGree ME, Roberts RO, and Girman CJ, et al. (2006). “Association of anthropometric measures with the presence and progression of benign prostatic hyperplasia”, Am J Epidemiol, Vol.164, p.41.
Choi J, Ikeguchi EF, Lee SW, Choi HY, Te AE, and Kaplan SA. (2002). “Is the higher prevalence of benign prostatic hyperplasia related to lower urinary tract symptoms in Korean men due to a high transition zone index?”, Eur Urol, Vol.42(1), pp.7–11.
Chopra IJ, and Tulchinsky D, et al. (1973). “Estrogen-androgen imbalance in hepatic cirrhosis: studies in 13 male patients”, Ann Intern Med, Vol.79(2), pp.198-203.
Dahle SE, Chokkalingam AP, and Gao YT, et al. (2002). “Body size and serum levels of insulin and leptin in relation to the risk of benign prostatic hyperplasia”, J Urol, Vol.168, pp.599–604.
Favilla V, Cimino S, Castelli T, Madonia M, Barbagallo I, and Morgia G. (2010). “Relationship between lower urinary tract symptoms and serum levels of sex hormones in men with symptomatic benign prostatic hyperplasia”, BJU International, Vol.106(11), pp.1700-1703.
Field AE, Colditz GA, and Willett WC. (1994). “The relation of smoking, age, relative weight and dietary intake to serum adrenal steroids, sex hormones and sex hormone-binding globulin in middle aged men”, J Clin Endocrinol Metab, Vol.79, pp.1310-1316.
Fowke JH, Murff HJ, Signorello LB, Lund L, and Blot WJ. (2008). “Race and socioeconomic status are independently associated with benign prostatic hyperplasia, J Urol, November, Vol.180(5), pp.2091-2096, doi: 10.1016/j.juro.2008.07.059.
Gann PH, Hennekens CH, Longcope C, and Stampfer MJ. (1995). A prospective study of plasma hormone levels, nonhormonal factors and development of benign prostatic hyperplasia”, Prostate, Vol.26(1), pp.40-49.
Gass R. (2002). “Benign prostatic hyperplasia: the opposite effects of alcohol and coffee intake”, BJU Int, Vol.90, pp.649-654.
Giovannucci E, Rimm EB, and Chute CG, et al. (1994). “Obesity and benign prostatic hyperplasia”, Am J Epidemiol, Vol.140, pp.989-1002.
Glynn RJ, and Campion EW, et al. (1985). “The development of benign prostatic hyperplasia among volunteers in the normative aging study”, Am J Epidemiol, Vol.121(1), pp.78-90.
Gordon GG, Altman K, and Southren AL et al. (1976). “Effect of alcohol (ethanol) administration on sex-hormone metabolism in normal men”, N Engl J Med, Vol.295, pp.793-797.
Guess HA. (1992). “Benign prostatic hyperplasia: antecedents and natural history”, Epidemiol Rev, Vol.14, pp.131-153.
Gupta A, Gupta S, Pavuk M, and Roehrborn CG. (206). “Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans”, Urology, Vol.68, pp.1198-1205.
Haffner S, and Taegtmeyer H. (2003). “Epidemic obesity and the metabolic syndrome”, Circulation, Vol.108, p.1541.
Haidinger G, Madersbacher S, and Waldhoer T, et al. (1999). “The prevalence of lower urinary tract symptoms in Austrian males and associations with sociodemographic variables”, Eur J Epidemiol, Vol.15, pp.717-722.
Hall SA, and Link CL, et al. (2009). “Urological symptom clusters and health-related quality-of-life: results from the Boston Area Community Health Survey”, BJU Int, Vol.103, pp.1502-1508.
Hammarsten J, and Högstedt B. (2001). “Hyperinsulinaemia as a risk factor for developing benign prostatic hyperplasia”, Eur Urol, Vol.39, pp.151-158.
Hammarsten J, Högstedt B, Holthuis N, and Mellström D. (1998). “Components of the metabolic syndrome-risk factors for the development of benign prostatic hyperplasia”, Prostate Cancer Prostatic Dis, Vol.3, pp.157-162.
Jin B, Turner L, Zhou Z, Zhou EL, and Handelsman DJ. (1999). “Ethnicity and migration as determinants of human prostate size”, J Clin Endocrinol Metab, October, Vol.84(10), pp.3613-3619.
Kim WT, Yun SJ, Choi YD, Kim GY, Moon SK, Choi YH, Kim IY, and Kim WJ. (2011). “Prostate Size Correlates with Fasting Blood Glucose in Non-Diabetic Benign Prostatic Hyperplasia Patients with Normal Testosterone Levels”, J Korean Med Sci, September, Vol.26(9), pp.1214-1218.
Kristal AR, Arnold KB, Schenk JM, Neuhouser ML, Weiss N, Goodman P, Antvelink CM, and Penson DF. (2007). “Thompson Race/ethnicity, obesity, health related behaviors and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial”, IM J Urol, April, Vol.177(4), p.13.
Kristal AR, Schenk JM, Song Y, Arnold KB, Neuhouser ML, and Goodman PJ, et al. (2008). “Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: Results from the prostate cancer prevention trial”, Am J Epidemiol, Vol.168, pp.1416-1424.
Kristal AR, et al. (2008). “Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the Prostate Cancer Prevention Trial”, American Journal of Epidemiology, Vol.167(8), Advance access publication, DOI: 10.1093/aje/kwm389.
Küpeli B, Soygür T, Aydos K, Ozdiler E, and Küpeli S. (1997). “The role of cigarette smoking in prostatic enlargement”, Br J Urol, August, Vol.80(2), pp.201-204.
Lee S, Min HG, Choi SH, Kim YJ, Oh SW, and Kim YJ et al. (2006). “Central obesity as a risk factor for prostatic hyperplasia”, Obesity, Silver Spring, Vol.14, p.172.
Lekili M, Muezzinoglu T, Uyanik BS, and Buyuksu C. (2006). “Serum lipid levels in benign prostatic hyperplasia”, World J Urol, Vol.24, pp.210-213.
Liu CC, Huang SP, Li WM, Wang CJ, Chou YH, Li CC, Huang CH, and Wu WJ. (2007). “Relationship between serum testosterone and measures of benign prostatic hyperplasia in aging men”, Urology, October, Vol.70(4), pp.677-680.
Lytton B, Emery JM, and Harvard BM. (1968). "The incidence of benign prostatic obstruction", J Urol, Vol.99, pp.639-645.
Mangal A, Kumar V, Panesar S, Talwar R, Raut D, and Singh S. (2015). “Updated BG Prasad socioeconomic classification, 2014: A commentary”, Indian J Public Health, Vol.59, pp.42-44.
Marberger M, Roehrborn CG, Marks LS. Wilson T, and Rittmaster RS. (2006). “Relationship among serum testosterone, sexual function and response to treatment in men receiving dutasteride for benign prostatic hyperplasia” J Clin Endocrinol Metab, Vol.91, pp.1323-1328.
Matzkin H, and Soloway MS. (1993). “Cigarette smoking: a review of possible associations with benign prostatic hyperplasia and prostate cancer”, Prostate, Vo.22(4), pp.277-290.
Matzkin H, Cytron S, and Simon D. (1996). “Is there an association between cigarette smoking and gland size in benign prostatic hyperplasia?”, Prostate, Vol.29, pp.42-45.
Meigs JB, Mohr B, and Barry MJ et al. (2001). “Risk factors for clinical benign prostatic hyperplasia in a community-based population of healthy aging men”, J. Clin Epid, Vol.54(9), pp.935-944.
Mitropoulos D, and Ploumidou KAK-V. (2003). “Hypercholesterol diet alters serum lipid profile and ventral prostate structure in rats”, Eur Urol Suppl, Vol.2(1), p.20.
Moon H, and Moon W, et al. (1995). “High prevalence of prostatism and benign prostatic hyperplasia in Korean men”, J Urol, Vol.155(Suppl.), p.631A.
Morote J, Encabo G, Lopez M, and de Torres IM. (2000). “Prediction of prostate volume based on total and free serum prostate specific antigen: is it reliable?”, Eur Urol, Vol.38, pp.91-95.
Morrison AS. (1992). “Risk factors for surgery for prostatic hypertrophy”, Am J Epidemiol, Vol.135, pp.974-980.
Nandeesha H, Koner BC, Dorairajan LN, and Sen SK. (2006). “Hyperinsulinemia and dyslipidemia in non-diabetic benign prostatic hyperplasia”, Clin Chim Acta, Vol.370, pp.89-93.
Nicholson TM, and Ricke WA. (2011). “Androgens and estrogens in benign prostatic hyperplasia: Past, present and future”, Differentiation, Vol.82, pp.184-199.
Padley R, and Olson P, et al. (1997). “Education and socio-economic status influence patterns of response to therapy with the alpha adrenergic receptor blocker terazosin and placebo in men with clinical benign prostatic hyperplasia (BPH)”, J Urol, Vol.157, p.312A.
Parsons JK, Bergstrom J, and Barrett CE. (2008). “Lipids, Lipoproteins and Risk of Benign Prostatic Hyperplasia in Community Dwelling Men”, BJU Int, Vol.101, pp.313-318.
Parsons JK, Carter HB, Partin AW, Windham BG, Metter EJ, Ferrucci L, Landis P, and Platz EA. (2006). “Metabolic factors associated with benign prostatic hyperplasia”, J Clin Endocrinol Metab, Vol.91, pp.2562-2568.
Parsons JK, et al. “Diabetes tied to enlarged Prostate”, available online: http://www.diabetesincontrol.com/53-diabetes/3991.com.
Parsons JK, Palazzi-Churas K, Bergstrom J, and Barrett-Connor E. (2010). “Prospective study of serum dihydrotestosterone and subsequent risk of benign prostatic hyperplasia in community dwelling men: The Rancho Bernardo Study”, J Urol, Vol.184, pp.1040-1044.
Partin AW, Oesterling JE, and Epstein JI, et al. (1991). “Influence of age and endocrine factors on the volume of benign prostatic hyperplasia”, J Urol, Vol.145, pp.405–409.
Rahman NU, Phonsombat S, Bochinski D, Carrion RE, Nunes L, and Lue TF. (2007). “An animal model to study lower urinary tract symptoms and erectile dysfunction: the hyperlipidaemic rat”, BJU Int, Vol.100, pp.658-663.
Roberts RO, Jacobson DJ, and Rhodes T, et al. (2004). “Serum sex hormones and measures of benign prostatic hyperplasia”, Prostate, Vol.61, pp.124-131.
Roehrborn CG. (2012). “Benign Prostatic Hyperplasia : Etiology, Pathophysiology, Epidemiology, and Natural History”, Campbell-Walsh Urology, Elsevier Inc, edition 10, chapter 91, pp.2570-2610.
Roehrborn CG, Boyle P, Gould AL, and Waldstreicher J. (1999). “Serum prostate specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia”, Urology, Vol.53, pp.581-589.
Roehrborn CG, Malice MP, Cook TJ, and Girman CJ. (2001). “Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: A comprehensive analysis of the pooled placebo groups of several large clinical trials”, Urology, Vol.58, pp.210-216.
Roehrborn CG, McConnell JD, Saltzman B, Bergner D, Gray T, Narayan P, Cook TJ, Johnson-Levonas AO, Quezada WA, and Waldstreicher J. (2002). “PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes”, Eur Urol, Vol.42, pp.1-6.
Rohrmann S, Smit E, Giovannucci E, and Platz EA. (2005). “Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III)”, Int J Obes, Lond, Vol.29, pp.310-316.
Safarinejad MR. (2008). “Prevalence of benign prostatic hyperplasia in a population-based study in Iranian men 40 years old or older”, Int Urol Nephrol, January, Vol.40(4), pp.921-931.
Signorello LB, Tzonou A, and Lagiou P, et al. (1999). “The epidemiology of benign prostatic hyperplasia: a study in Greece”, BJU Int, Vol.84, pp.286-291.
Seidell JC, Bjorntorp P, and Sjostrom L, et al. (1990). “Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels”, Metabolism, Vol.39, pp.897-901.
Seim A, Hoyo C, Ostbye T, and Vatten L. (2005). “The prevalence and correlates of urinary tract symptoms in Norwegian men: the HUNT study”, BJU Int, Vol.96, p.88.
Seitter WR, and Barrett-Connor E. (1992). “Cigarette smoking, obesity, and benign prostatic hypertrophy: a prospective population-based study”, Am J Epidem, Vol.135, pp.500-503.
Sidney S, Quesenberry C Jr, and Sadler MC, et al. (1991). “Risk factors for surgically treated benign prostatic hyperplasia in a prepaid health care plan”, Urology, Vol.38, pp.13-19.
Siiteri PK. and Wilson, JD. (1970). “Dihydrotestosterone in prostatic hypertrophy. The formation and Content of dihydrotestosterone in the hypertrophic prostate of man”, J Clin. Invest, Vol.49(9), pp.1737-1745.
St Sauver JL, Jacobson DJ, McGree ME, Girman CJ, Klee GG, Lieber MM, and Jacobsen SJ. (2011). “Associations Between Longitudinal Changes in Serum Estrogen, Testosterone, and Bioavailable Testosterone and Changes in Benign Urologic Outcomes”, Am J Epidemiol, Apr 1, Vol.173(7), pp.787-796.
Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, and Redwine E. (1987). “Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate”, N Engl J Med, Vol.317, pp.909-916.
Tanagho EA, and McAninch JW. (2003). “Smith’s General Urology”, 17th edition, Chapter 22, “Neoplasm of prostate gland”, Tata McGraw Hill, p.348.
Tewari R, Prabhat P, Natu SM, Dalela D, Goel A, Goel MM, and Tandon P. (2011). “Association of benign prostatic hyperplasia (BPH) with metabolic syndrome (MS) and its components: A growing dilemma”, J Mens Health, Vol.8, pp.66-71.
Trifiro MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C, and Barrett-Connor E. (2010). “Serum sex hormones and the 20-year risk of lower urinary tract symptoms in community-dwelling older men”, BJU Int, Vol.105, pp.1554-1559.
Vesely S, Knutson T, Damber JE, Dicuio M, and Dahlstrand C. (2003). “Relationship between age, prostate volume, prostate-specific antigen, symptom score and uroflowmetry in men with lower urinary tract symptoms”, Scand J Urol Nephrol, Vol.37, pp.322-328.
Walsh PC. (1988). “The role of estrogen/androgen synergism in the pathogenesis of benign prostatic hyperplasia”, J Urol, Vol.139, p.826.
Walsh PC, Hutchins GM, and Ewing LL. (1983). “The tissue content of dihydrotestosterone human prostatic hyperplasia is not supranormal”, J. Clin. Invest, Vol.72, pp.1772-1777.
Wilson JD. (1980). “The pathogenesis ofbenign prostatic hyperplasia”, Am. J Med, Vol.68, p.745.
Zucchetto A, Tavani A, Dal Maso L, Gallus S, Negri E, and Talamini R, et al. (2005). “History of weight and obesity through life and risk of benign prostatic hyperplasia”, Int J Obes, Lond, Vol.29, p.798.
Refbacks
- There are currently no refbacks.
Send mail to ijsss@ijsss.com with questions or comments about this web site.
International Journal of Surgery and Surgical Sciences, All rights reserved.